MLX0487-23 / METiS Pharmaceuticals - LARVOL DELTA

mRNA-encoded HPV16/18 therapeutic vaccine with co-stimulator to activate antigen presenting cells and promote T cell-mediated anti-tumor activity (AACR 2025) - "We conclude that MLX0487-23 (LNP) encapsulated P016-2, a 4 antigen and GM-CSF expressing mRNA, effectively expanded HPV-specific CD8+ T cells and mediated potent anti-tumor efficacy in the preclinical models, making it an excellent candidate therapeutic mRNA vaccine for clinical testing its safety and efficacy in HPV-driven malignancies."

Cervical Cancer • Oncology • Solid Tumor • CD8 • CSF2 • TNFSF4